Summary of change in the 3.2013 version of the Guidelines for the Colon Cancer from the 1.2013 version include:
COL-C 3 of 9
FOLFOX and Capeox added as treatment options in therapy after second progression for patients treated previously with irinotecan-based chemotherapy.
